JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

Search

Bio-Techne Corp

Закрыт

СекторЗдравоохранение

65.87 -0.23

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

65.74

Макс.

66.29

Ключевые показатели

By Trading Economics

Доход

-40M

-18M

Продажи

783K

317M

P/E

Средняя по отрасли

135.957

37.461

Прибыль на акцию

0.53

Дивидендная доходность

0.52

Рентабельность продаж

-5.577

Сотрудники

3,100

EBITDA

-61M

6.4M

Рекомендации

By TipRanks

Рекомендации

Активная покупка

Прогноз на 12 месяцев

+1.97% upside

Дивиденды

By Dow Jones

Дивидендная доходность

Средняя по отрасли

0.52%

2.33%

Следующий отчет о доходах

5 нояб. 2025 г.

Дата следующей выплаты дивидендов

21 нояб. 2025 г.

Следующая эксдивидендная дата

10 нояб. 2025 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

847M

9.7B

Предыдущая цена открытия

66.1

Предыдущая цена закрытия

65.87

Новостные настроения

By Acuity

50%

50%

148 / 373 Рейтинг в Healthcare

Техническая оценка

By Trading Central

Уверенность

Weak Bullish Evidence

Bio-Techne Corp График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

26 окт. 2025 г., 23:52 UTC

Обсуждения рынка

Global Equities Roundup: Market Talk

26 окт. 2025 г., 23:52 UTC

Обсуждения рынка

Nikkei May Rise on Weaker Yen -- Market Talk

26 окт. 2025 г., 23:46 UTC

Обсуждения рынка

Oil Rises Amid Ongoing Supply Concerns -- Market Talk

26 окт. 2025 г., 23:41 UTC

Обсуждения рынка

Gold Falls; U.S.-China Trade Deal Optimism Overcomes Signs of Cooler U.S. Inflation -- Market Talk

26 окт. 2025 г., 23:34 UTC

Отчет

Sinopharm Group 9-Mos Oper Pft CNY10.87B Vs. Pft CNY10.84B >1099.HK

26 окт. 2025 г., 23:32 UTC

Отчет

Sinopharm Group 9-Mos Net CNY5.31B Vs. Net CNY5.28B >1099.HK

26 окт. 2025 г., 23:30 UTC

Отчет

Sinopharm Group 9-Mos Rev CNY431.48B Vs. CNY442.42B >1099.HK

26 окт. 2025 г., 22:29 UTC

Отчет

WuXi AppTec 3Q Rev CNY12.06B ; up 15.3% on Year>603259.SH

26 окт. 2025 г., 22:29 UTC

Отчет

WuXi AppTec: Higher Contributions From Contract Research Development and Manufacturing Organization Unit Supported Results>603259.SH

26 окт. 2025 г., 22:29 UTC

Отчет

WuXi AppTec: Results Also Boosted From Divestment Gains >603259.SH

26 окт. 2025 г., 22:29 UTC

Отчет

WuXi AppTec 3Q Net CNY5.13B ; up 82.9% on Year>603259.SH

26 окт. 2025 г., 22:16 UTC

Отчет

Stock Futures Rise Ahead of Mag 7 Earnings, Fed Decision -- Barrons.com

26 окт. 2025 г., 21:33 UTC

Приобретения, слияния, поглощения

Novartis Agrees to Acquire Avidity Biosciences for $12 Billion -- WSJ

26 окт. 2025 г., 19:29 UTC

Приобретения, слияния, поглощения

Novartis Deal Values Avidity Biosciences At $12 Billion -- Barrons.com

26 окт. 2025 г., 06:39 UTC

Отчет

CITIC Securities 3Q Rev CNY22.78B Vs. CNY15.96B >6030.HK

26 окт. 2025 г., 06:39 UTC

Отчет

CITIC Securities: Higher Income From Brokerage, Investment Banking Supported Results>6030.HK

26 окт. 2025 г., 06:39 UTC

Отчет

CITIC Securities 3Q Net CNY9.44B Vs. Net CNY6.23B >6030.HK

24 окт. 2025 г., 21:24 UTC

Обсуждения рынка

Global Forex and Fixed Income Roundup: Market Talk

24 окт. 2025 г., 21:24 UTC

Обсуждения рынка

Moody's Sees France With Increased Risk of Political Dysfunction -- Market Talk

24 окт. 2025 г., 21:07 UTC

Отчет

The Score: Netflix, Amazon.com, Six Flags and More Stocks That Defined the Week -- WSJ

24 окт. 2025 г., 20:58 UTC

Отчет

S&P 500 Climbs to New Record on Strong Earnings -- WSJ

24 окт. 2025 г., 20:50 UTC

Обсуждения рынка

Financial Services Roundup: Market Talk

24 окт. 2025 г., 20:40 UTC

Отчет

Intel Expects Chip Shortages on Better PC Demand. Here's Why AMD Is Winning Too. -- Barrons.com

24 окт. 2025 г., 20:24 UTC

Отчет

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24 окт. 2025 г., 20:23 UTC

Отчет

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24 окт. 2025 г., 20:13 UTC

Отчет

These Stocks Moved the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 окт. 2025 г., 20:07 UTC

Обсуждения рынка

Different-Cell Imputation Rose Proportionally in September CPI -- Market Talk

24 окт. 2025 г., 19:40 UTC

Обсуждения рынка

Treasury Yields Mixed, Dollar Stronger Ahead of Fed Week -- Market Talk

24 окт. 2025 г., 19:35 UTC

Обсуждения рынка

Oil Rally on U.S. Russia Sanctions Loses Steam -- Market Talk

24 окт. 2025 г., 19:33 UTC

Отчет

IBM and Google Are Also Making Moves in Quantum. Don't Count Out the Bigger Players. -- Barrons.com

Сравнение c конкурентами

Изменение цены

Bio-Techne Corp Прогноз

Целевая цена

By TipRanks

1.97% рост

Прогноз на 12 месяцев

Средняя 67.2 USD  1.97%

Максимум 75 USD

Минимум 53 USD

Основано на мнении 13 аналитиков Wall Street, спрогнозировавших целевые цены для Bio-Techne Corp на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

13 ratings

10

Покупка

3

Удержание

0

Продажа

Техническая оценка

By Trading Central

49.67 / 50.24Поддержка и Сопротивление

Краткосрочная

Weak Bullish Evidence

Среднесрочная

Weak Bullish Evidence

Долгосрочная

Strong Bearish Evidence

Настроения

By Acuity

148 / 373Рейтинг в Здравоохранение

Новостные настроения

Neutral

Волатильность

Ниже среднего

Объем новостей (RCV)

Ниже среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Bio-Techne Corp

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company has strategic partnership with ALZpath, Inc. to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
help-icon Live chat